Gen9 is building on advances in synthetic biology to power a scalable fabrication capability that will significantly increase the world's capacity to compile DNA content.
Our next-generation DNA synthesis technology allows for the high-throughput, automated production of DNA constructs at lower cost and higher accuracy than previous methods on the market.
Gen9 aims to ensure the constructive application of synthetic biology in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels.
What's New at Gen9 |
|
Read CEO, Kevin Munnelly's new article on Engineering for the 21st Century - May 7, 2013
Gen9 sponsors Mammalian Synthetic Biology Workshop - May 11-12 at MIT
Gen9 Receives $21 Million Strategic Investment from Agilent Technologies - Apr 24, 2013
Gen9 is hiring: Production Sr. Scientist, Product Applications Scientist, Sr. SW Engineer
A discussion with synthetic biology pioneers Drew Endy, George Church, and David Baker
Read COO, Martin Goldberg's new article on Applying Moore's Law to DNA Synthesis
The Scientist names Gen9 Technology #1 in the Top Ten Innovations of 2012
![]() |




